{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T17:27:09Z","timestamp":1774114029077,"version":"3.50.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,1]]},"DOI":"10.1164\/rccm.201706-1105le","type":"journal-article","created":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T16:07:57Z","timestamp":1498493277000},"page":"1230-1231","source":"Crossref","is-referenced-by-count":2,"title":["Reply: What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease?"],"prefix":"10.1093","volume":"196","author":[{"given":"Nicolas","family":"Roche","sequence":"first","affiliation":[{"name":"University Paris Descartes, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth R.","family":"Chapman","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus F.","family":"Vogelmeier","sequence":"additional","affiliation":[{"name":"Philipps-Universit\u00e4t Marburg, Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix J. F.","family":"Herth","sequence":"additional","affiliation":[{"name":"German Center for Lung Research, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chau","family":"Thach","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Fogel","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3913-3914","authenticated-orcid":false,"given":"Petter","family":"Olsson","sequence":"additional","affiliation":[{"name":"Novartis Sverige AB, T\u00e4by, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Patalano","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Banerji","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadwiga A.","family":"Wedzicha","sequence":"additional","affiliation":[{"name":"Imperial College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,11,1]]},"reference":[{"key":"2026032023472732400_bib1","author":"Global Initiative for Chronic Obstructive Lung Disease"},{"key":"2026032023472732400_bib2","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N Engl J Med"},{"key":"2026032023472732400_bib3","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1164\/rccm.201701-0193OC","article-title":"Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment: data from the FLAME trial","volume":"195","author":"Roche","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023472732400_bib4","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","article-title":"Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial","volume":"4","author":"Watz","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2026032023472732400_bib5","article-title":"Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease [letter]","author":"Calverley","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023472732400_bib6","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","article-title":"Withdrawal of inhaled glucocorticoids and exacerbations of COPD","volume":"371","author":"Magnussen","year":"2014","journal-title":"N Engl J Med"},{"key":"2026032023472732400_bib7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2147\/COPD.S119908","article-title":"Comparative efficacy of long-acting \u03b22-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis","volume":"12","author":"Donohue","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026032023472732400_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026032023472732400_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1164\/rccm.201502-0235LE","article-title":"Blood eosinophils: a biomarker of response to extrafine beclomethasone\/formoterol in chronic obstructive pulmonary disease","volume":"192","author":"Siddiqui","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023472732400_bib10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","article-title":"Blood eosinophils and inhaled corticosteroid\/long-acting \u03b2-2 agonist efficacy in COPD","volume":"71","author":"Pavord","year":"2016","journal-title":"Thorax"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/196\/9\/1230\/67127344\/ajrccm_196_9_1230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/196\/9\/1230\/67127344\/ajrccm_196_9_1230.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:48:22Z","timestamp":1774064902000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/196\/9\/1230\/8499224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,1]]},"references-count":10,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,11,1]]},"published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201706-1105le","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,11]]},"published":{"date-parts":[[2017,11,1]]}}}